CUE Earnings

CUE reported its earnings on 2026-02-25, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0%. The stock experienced a 1.66% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CUE's earnings announcement on 2026-02-25, the stock price moved by 1.66% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, CUE's stock price tends to shift by an average of -8.01% in the 10 days leading up to earnings and -4.38% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CUE's annual revenue to reach 1.75M, while the EPS is projected at -0.10. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CUE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CUE's stock price typically moves by -8.01% in the 10 days before its earnings and -4.38% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.10 and revenue of 1.75M.

The earnings call summary presents a mixed outlook. Financial management shows improvement with reduced cash burn and extended runway, but challenges remain. The company's clinical data is promising, with significant improvements in treatment efficacy and survival outcomes, which is positive. However, there are concerns about regulatory risks, competitive pressures, and dependency on partnerships. The Q&A section highlights strategic interest and potential partnerships, but also reveals management's vague responses, particularly regarding milestone negotiations. Without a share repurchase program or clear guidance, the overall sentiment remains neutral.